Antiangiogenic agents and targets: A perspective

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 6-12

  Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Angiopoietins; CXCL12 CXCR4; CXCR2; HGF cMet; Notch; Placental growth factor; Sphingosine 1 phosphate; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; AXITINIB; BAVITUXIMAB; BEVACIZUMAB; BIBF 1120; BRIVANIB; CEDIRANIB; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; DOVITINIB; INTERLEUKIN 8; JNJ 38877605; LINIFANIB; MOTESANIB; PAZOPANIB; PF 4217903; PLACENTAL GROWTH FACTOR; PLERIXAFOR; PROTEIN TYROSINE KINASE INHIBITOR; RG 4733; SORAFENIB; SPHINGOSINE 1 PHOSPHATE; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB; XL 184;

ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 78549270044     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.023     Document Type: Note

References (95)

1. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009, 20:158-163.
2. Staton C.A., Brown N.J., Reed M.W.R. Current status and future prospects for anti-angiogenic therapies in cancer. Exp Opin Drug Discov 2009, 4:961-979.
3. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for Bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
4. Yang S.X. Bevacizumab and breast cancer: current therapeutic progress and future. Exp Rev Anticancer Ther 2009, 9:1715-1725.
5. Higa G.M. Breast cancer: beyond the cutting edge. Exp Opin Pharmacother 2009, 10:2479-2498.
6. Sarmiento R., D'Andrea M., Cacciamani F., Salerno F., Gasparini G. Antiangiogenic therapies in breast cancer. Curr Opin Invest Drugs 2009, 10:1334-1345.
7. Roy V., Perez E.A. Bioloigc therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat 2009, 116:31-38.
8. Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S., et al. Phase I pharmacologic and biologic study of ramucirumab 9IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28:780-787.
9. Chu D., Lacouture M.E., Fillos T., Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008, 47:176-186.
10. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
11. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
12. Sternberg C.N., Szczylik C., Lee E., Salman P.V., Mardiak J., Davis I.D., et al. A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(Suppl. 15s). [Abstr #5021].
13. Ainsworth N.L., Lee J.S.Z., Eisen T. Impact of anti-angiogenic treatment on metastatic renal cell carcinoma. Exp Rev Anticancer Ther 2009, 9:1793-1805.
14. Zhu A.X., Raymond E. Early development of sunitinib in heptacellular carcinoma. Exp Rev Anticancer Ther 2009, 9:143-150.
15. Autier J., Escudier B., Wechsler J., Spatz A., Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008, 144:886-892.
16. Theo-Anton N., Faivre S., Dreyer C., Raymond E. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumors and renal cancer. Drug Safety 2009, 32:717-734.
17. Carter C.A., Chen C., Brink C., Vincent P., Maxuitenko Y.Y., Gilbert K.S., et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007, 59:183-195.
18. Cumashi A., Tinari N., Rossi C., Lattanzio R., Natoli C., Piantelli M., et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008, 270:229-233.
19. Royce M., Chiorean E.G., Sweeney C., Verschraegen C., Lee F.C., Jones S., et al. A phase I dose-finding study of sunitinib in combination with capecitabine in patients with advanced solid tumors. ASCO Breast Cancer Symp 2008, [Abstr #169].
20. Polcher M., Eckhardt M., Coch C., Wolfgarten M., Kubler K., Hartmann G., et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010, 66. [online March 5].
21. ®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008, 61:535-548.
22. Gradishar W.J., Kaklamani V., Prasad Sahoo T., Lokanatha D., Raina V., Bondarde S., et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). San Antonio Breast Cancer Sym 2009, [Abstr #44].
23. Baselga J., Roche H., Costa F., Segalla J.G.M., Pinczowski H., Ciruelos E.M., et al. SOLTI-0701: a multinational double-blind, randomized Phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). San Antonio Breast Cancer Sym 2009, [Abstr #45].
24. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009, 2:re1-re11.
25. Heath V.L., Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009, 6:395-404.
26. Eikesdal H.P., Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009, 19:310-317.
27. Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., et al. Phase II trial of infusional fluorouracil, irinotecan and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010, 28:453-459.
28. Zurita A.J., Jonasch E., Wu H.K., Tran H.T., Heymach J.V. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 2009, 115:2346-2354.
29. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
30. Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
31. Escudero-Esparaza A., Martin T.A., Davies M.L., Jiang W.G. PlGF isoforms, PlGF-1 and PlGF-2 in colorectal cancer and the prognostic significance. Cancer Genom Proteom 2009, 6:239-246.
32. Albonici L., Doldo E., Palumbo C., Orlandi A., Bei R., Pompeo E., et al. Placenta growth factor is a survival factor for human malignant mesothelioma cells. Int J Immunopathol Pharmacol 2009, 22:389-401.
33. Pompeo E., Albonici L., Doldo E., Orlandi A., Manzari V., Modesti A., et al. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thor Surg 2009, 88:426-431.
34. Yang S., Cheng H., Cai J., Zhang J., Wang Z. PlGF, expression in pre-invasive and invasive lesions of uterine cervix is associated with angiogenesis and lymphangiogenesis. APMIS 2009, 117:831-838.
35. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a Historical review. Angiogenesis 2008, 11:215-221.
36. Hedlund E.M., Hosaka K., Zhong Z., Cao R., Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci USA 2009, 106:17505-17510.
37. Cao Y., Zhong W., Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009, 19:338-343.
38. Carmeliet P., De Smet F., Loges S., Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009, 6:315-326.
39. Chen C.N., Chang C.C., Su T.E., Hsu W.M., Jeng Y.M., Ho M.C., et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 2009, 16:524-533.
40. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 2008, 8:942-956.
41. Oliner J., Min H., Leal J., Yu D., Rao S., You E., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
42. Herbst R.S., Hong D., Chap L., Kurzrock R., Jackson E., Silverman J.M., et al. Safety, pharmacokinetics and antitumor activity of AMG-386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009, 27:3557-3565.
43. Mita A.C., Takimoto C.H., Mita M., Tolcher A., Sankhala, Sarantopoulos J., et al. Phase 1 study of AMG-386, a selective angiopoietin1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010, 16:3044-3056.
44. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931.
45. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 1-12.
46. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N.M., Stiff P.J., Kaufman J.L., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
47. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
48. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
49. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008, 28:1928-1936.
50. Singh S., Sadanandam A., Nannuru K.C., Varney M.L., Mayer-Ezell R., Bond R., et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival and angiogenesis. Clin Cancer Res 2009, 15:2380-2386.
51. Noonan D.M., De Lerma Barbaro A., Vannini N., Mortara L., Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Met Rev 2008, 27:31-40.
52. Crawford S., Belajic D., Wei J., Riley J.P., Dunford P.J., Bembenek S., et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker. Mol Cancer Ther 2008, 7:492-499.
53. Matsuo Y., Raimondo M., Woodward T.A., Wallace M.B., Gill K.R., Tong Z., et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009, 125:1027-1037.
54. Yanagawa J., Walser T.C., Zhu L.X., Hong L., Fishbein M.C., Mah V., et al. Snail promotes CXCR2 ligand-dependent tumor progression in noon-small cell lung carcinoma. Clin Cancer Res 2009, 15:6820-6829.
55. Neri F., Puviani L., Tsivian M., Prezzi D., Pacile V., Cavallari G., et al. Protective effect of an inhibitor of interleukin-8 (meraxin) from ischemia and reperfusion injury in a rat model of kidney transplantation. Transplant Proc 2007, 39:1771-1772.
56. Rizzo P., Osipo C., Foreman K., Golde T., Osborne B., Miele L. Rational targeting of notch signaling in cancer. Oncogene 2008, 27:5124-5131.
57. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
58. Thurston G., Noguera-Troise I., Yancopoulos G.D. The Delta paradox: DLL4 blockade leads to more tumor vessels but less tumor growth. Nat Rev Cancer 2007, 7:327-331.
59. Li J.L., Harris A.L. Crosstalk of VEGF and notch pathways in tumor angiogenesis: therapeutic implications. Front Biosci 2009, 14:3094-3110.
60. Blackman S.C., Podtelezhnikov A., Railkar R.A., Loboda A., Tanis K., Klappenbach J.A., et al. Notch pathway inhibition with MK-0752 leads to dose- and time-dependent transcriptional alterations in proliferation, PI3K and Wnt pathway genes in plucked human hair follicles. Proc Am Assoc Cancer Res 2010, 51. [Abstr #26].
61. Hernandez S.L., Funahashi Y., Sharma A., Kitajewski J.K., Kandel J.J., Yamashiro D.J., et al. VEGF regulate tumor endothelial cell survival. Proc Am Assoc Cancer Res 2010, 51. [Abstr #1282].
62. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., deLeon G.P., Chen Y., et al. Therapeutic antibody targeting of individual notch receptors. Nature 2010, 464:1052-1059.
63. Okamura H., Lorusso J., Bell A., Perino S., Keane D., Brodeur J., et al. Monoclonal antibodies to notch receptors inhibit tumor maintenance. Proc Am Assoc Cancer Res 2010, 51. [Abstr #5170].
64. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
65. Marsolais D., Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutics molecules. Nat Rev Drug Discov 2009, 8:297-307.
66. Ader I., Malavaud B., Cuvillier O. When the sphingosine kinase 1/sphingosine-1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res 2009, 69:3723-3726.
67. Ishii M., Egen J.G., Klauschen F., Meier-Schellersheim M., Saeki Y., Vacher J., et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009, 458:524-528.
68. Li W., Yu C.P., Xia J., Zhang L., Weng G.X., Zheng H., et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009, 15:1393-1399.
69. Kapitonov D., Allegood J.C., Mitchell C., Hait N.C., Almenara J.A., Adams J.K., et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009, 69:6915-6923.
70. O'Brien N., Jones S.T., Williams D.G., Cunningham H.B., Moreno K., Visentin B., et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res 2009, 50:2245-2257.
71. Gordon M.S., Just R., Rosen L.S., Dorr A. A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors. J Clin Oncol 2010, 28(7s). [Abstr #2560].
72. Callalero S., Swaney J., Moreno K., Afzal A., Kielczewski J., Stoller G., et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a mutrine model of laser-induced choroidal neovascularization. Exp Eye Res 2009, 88:367-377.
73. Eder J.P., Vande Woude G.F., Boerner S.A., LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15:2207-2214.
74. Lee K.H., Kim J.R. Hepatocyte growth factor induced up-regulation of VEGF through Egr-1in hepatocellular carcinoma cells. Clin Exp Metastases 2009, 26:685-692.
75. Karamouzis M.V., Konstantinopoulos P.A., Papavassiliou A.G. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009, 10:709-717.
76. Rischin D., Fisher R., Oliner K., Young R.J., Cao H., McArthur G.A., et al. Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) inpatients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. J Clin Oncol 2010, 28s. [Abstr #5509].
77. Kubota T., Taiyoh H., Matsumura A., Murayama Y., Ichikawa D., Okamoto K., et al. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis 2009, 26:447-456.
78. Qian F., Engst S., Yamaguchi K., Yu P., Won K.A., Mock L., et al. Inhibition of tumor cell growth, invasion and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009, 69:8009-8016.
79. Jones S.F., Cohen R.B., Bendell J.C., Denlinger C.S., Harvey R.D., Parasuraman S., et al. Safety, tolerability and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: first-in-human phase I dose-escalation study. J Clin Oncol 2010, 28s. [Abstr #3081].
80. Patnaik A., Weiss G.J., Papadopoulos K., Tibes R., Tolcher A.W., Payumo F.C., et al. Phase I study of SCH900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients with advanced tumors. J Clin Oncol 2010, 28s. [Abstr #2525].
81. Moss R.A., Bothos J.G., Filvaroff E., Merchant M., Eppler S., Yu W., et al. Phase Ib dose escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors. J Clin Oncol 2010, 28s. [Abstr #el3050].
82. Andre F., Baselga J., Ellis M.J., Hurvitz S.A., Rugo H.S., Turner N.C., et al. Study CTKI258A2202: a multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. J Clin Oncol 2010, 28. [Abstr #TPS122].
83. Angevin E., Lin C., Pande A.U., Lopez J.A., Gschwend J., Harzstark A.L., et al. A phase I/II study of dovitinib (TKI258), a FGFr and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. J Clin Oncol 2010, 28. [Abstr #3057].
84. Prenen H., D'Haens G., Capdevila J., Carrato A., Sobrero A., Ducreux M., et al. A phase I dose escalation study of BIBF1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol 2010, 28. [Abstr #e14054].
85. Tebbutt N.C., Kotasek D., Burris H.A., Schwartzberg L.S., Hurwitz H., Stephenson J., et al. Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 2010, 28. [Abstr #3538].
86. Blumenschein G.R., Kabbinavar F.F., Menon H., Mok T., Stephenson J., Beck J.J., et al. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28. [Abstr #7528].
87. Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L., Sakakibara A., et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
88. Sawamiphak S., Seidel S., Essmann C.L., Wilkinson G.A., Pitulescu M.E., Acker T., et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumor angiogenesis. Nature 2010, 465:487-491.
89. Ball S.G., Shuttleworth C.A., Kielty C.M. Platelet-derived growth factor receptors regulate mesenchymal stem cell fate: implications for neovascularization. Expert Opin Biol Ther 2010, 10:57-71.
90. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8:235-253.
91. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009, 106:6742-6747.
92. Shi M., Kim K.B., Chesney J., Wang X., Motwani M., Wang J., et al. Effect of TKI258 on plasma biomarkers and pharmacokinetics in patients with advanced melanoma. J Clin Oncol 2009, 27 Suppl.. [Abstr 9020].
93. Novartis; data on file.
94. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
95. Kanai F., Yoshida H., Tateishi R., Sato S., Kawabe T., Obi S., et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010, [published online April 2010].